Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relugolix combination therapy for heavy menstrual bleeding associated with uterine fibroids (ChiCTR2400088811)
ChiCTR2400088811Phase 3Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Aug 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Fibromyoma (LM) and hypermenorrhea comparing Relugolix combination arm with Placebo combination arm (2 arms). Primary endpoint: Proportion of subjects with MBL < 80 mL and ≥ 50% reduction from baseline. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
tissue-plasminogen activator
03
Conditions
Fibromyoma (LM)hypermenorrhea
Beyond the preview
Go deeper on ChiCTR2400088811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088811.